Medicines for Malaria Venture’s Post

🚀 Proud to share our latest research publication 🚀 Our team has conducted a study titled :Prescribing Patterns of Intravenous Artesunate for Severe Malaria and Compliance with National Malaria Treatment Protocol, Gezira State, Sudan. This work, carried out in collaboration with experts from the Ministry of Health, University of Khartoum, University of Gezira, and international partners, focuses on assessing the adherence to national protocols in treating severe malaria with intravenous artesunate. 🩺 Key Highlights: - Analyzing the prescribing patterns for severe malaria. - Evaluating compliance with the national treatment protocols in Sudan. - Collaboration across multiple disciplines including clinical pharmacology, gastroenterology, and pharmaceutical chemistry. Grateful to work alongside my talented colleagues: Arwa Ali Salih Alhaj Ali, Elfatih Mohamed Malik, Mohammed Taha Hussein, Anwar Mohammed Abdelrahman, and Suha Gafar Mohamedkhair Ibrahim. A special thanks to the healthcare professionals and institutions involved in this critical study that aims to improve malaria treatment outcomes in Sudan. Let's continue pushing boundaries in healthcare research to save lives! 💪 #MalariaResearch #Healthcare #Pharmacology #Sudan #PublicHealth

Our joint paper published this month in Microbiology Spectrum discusses a study on the Plasmodium falciparum parasite’s ability to resist artemisinin-based medicines, which are the first-line treatment for malaria recommended by the World Health Organization. In “Drug-induced stress mediates Plasmodium falciparum ring-stage growth arrest and reduces in vitro parasite susceptibility to artemisinin”, Lucien Platon and Didier Menard (Institut Pasteur), Didier Leroy (MMV) and David Fidock (Columbia University) reveal that the P. falciparum parasite has a survival mechanism that enables it to stop its growth when exposed to artemisinin derivatives. This discovery adds new insights to understanding how malaria parasites survive and adapt to drugs, highlighting the role of communication between cells in this process. Read the paper: https://bit.ly/3wymFfX

#𝐀𝐧𝐭𝐢 #𝐌𝐚𝐥𝐚𝐫𝐢𝐚𝐥 #𝐃𝐫𝐮𝐠𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐄𝐱𝐩𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐆𝐫𝐨𝐰 𝐚𝐭 4.3% 𝐂𝐀𝐆𝐑, 𝐑𝐞𝐚𝐜𝐡𝐢𝐧𝐠 𝐔𝐒$ 1333.16 𝐌𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2030 𝐅𝐨𝐫 𝐚𝐧 𝐢𝐧-𝐝𝐞𝐩𝐭𝐡 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬, 𝐜𝐥𝐢𝐜𝐤 𝐭𝐡𝐞 𝐩𝐫𝐨𝐯𝐢𝐝𝐞𝐝 𝐥𝐢𝐧𝐤: https://lnkd.in/dmVhSJYQ The #anti-malarial drugs market is poised for steady growth with a projected CAGR of 4.3% during the forecast period, aiming to reach approximately US$ 1333.16 million by 2030. This #growth is driven by persistent efforts to combat malaria, a major global health concern, particularly in regions with high #transmission rates such as sub-Saharan Africa and parts of Southeast Asia. Key factors #contributing to market expansion include ongoing research and development initiatives focused on developing more effective and affordable treatments, as well as increasing #healthcare investments aimed at improving access to anti-malarial therapies in vulnerable populations. Additionally, public health #campaigns and international collaborations continue to play a crucial role in advancing treatment options and reducing the burden of malaria worldwide. 𝑪𝒐𝒎𝒑𝒆𝒕𝒊𝒕𝒊𝒗𝒆 𝑳𝒂𝒏𝒅𝒔𝒄𝒂𝒑𝒆: 1. Mylan Labs 2. Cipla 3. GlaxoSmithKline Consumer Healthcare, L.P. 4. Novartis 5. Roche #𝐀𝐧𝐭𝐢𝐌𝐚𝐥𝐚𝐫𝐢𝐚 #𝐌𝐚𝐥𝐚𝐫𝐢𝐚𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 #𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 #𝐆𝐥𝐨𝐛𝐚𝐥𝐇𝐞𝐚𝐥𝐭𝐡 #𝐏𝐮𝐛𝐥𝐢𝐜𝐇𝐞𝐚𝐥𝐭𝐡 #𝐈𝐧𝐟𝐞𝐜𝐭𝐢𝐨𝐮𝐬𝐃𝐢𝐬𝐞𝐚𝐬𝐞𝐬 #𝐃𝐫𝐮𝐠𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 #𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞𝐀𝐜𝐜𝐞𝐬𝐬 #𝐆𝐥𝐨𝐛𝐚𝐥𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞 #𝐌𝐚𝐥𝐚𝐫𝐢𝐚𝐏𝐫𝐞𝐯𝐞𝐧𝐭𝐢𝐨𝐧 #𝐇𝐞𝐚𝐥𝐭𝐡𝐄𝐪𝐮𝐢𝐭𝐲 #𝐌𝐞𝐝𝐢𝐜𝐚𝐥𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 #𝐄𝐩𝐢𝐝𝐞𝐦𝐢𝐨𝐥𝐨𝐠𝐲 #𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬 #𝐆𝐥𝐨𝐛𝐚𝐥𝐇𝐞𝐚𝐥𝐭𝐡𝐈𝐧𝐢𝐭𝐢𝐚𝐭𝐢𝐯𝐞𝐬

🚀 Fresh from the Host-Pathogen Interactions lab at iMed.ULisboa, a new paper titled “Ethambutol and meropenem/clavulanate synergy promotes enhanced extracellular and intracellular killing of Mycobacterium tuberculosis” has just been #Published. 📚Increasing evidence supports the repositioning of beta-lactams for tuberculosis (TB) therapy, but further research on their interaction with conventional anti-TB agents is still warranted. This study aimed to identify synergies between beta-lactams and anti-TB drugs ethambutol and isoniazid by assessing antimicrobial effects, intracellular activity, and immune responses. Ultimately, it demonstrated that pairing beta-lactams with ethambutol significantly improves their efficacy against Mycobacterium tuberculosis. (Adapted from the Abstract.) 💥 Congratulations to the authors Francisco Olivença, David Pires, Cátia Silveiro, Bianca Gama, Frederico Holtreman, Elsa Anes, Maria João Catalão! 🔎 You can read the full article here: https://lnkd.in/gJKWZNYG #MycobacteriumTuberculosis, #AntimicrobialResistance, #Carbapenems, #AntibioticSynergy

Synthesis and In Vivo Profiling of Desymmetrized Antimalarial #Trioxolanes with Diverse Carbamate Side Chains. Despite notable progress in the #preclinical arena, malaria remains a cause of significant mortality, particularly in sub-Saharan Africa. #Artemisinin-based combination therapy, the standard treatment for uncomplicated malaria, and intravenous artesunate, the standard for severe malaria, are threatened by the increasing prevalence of artemisinin partial resistance (ART-R), which has recently emerged in eastern Africa. The recent #withdrawal of #artefenomel from clinical development leaves no #endoperoxide-class agents in the antimalarial pipeline, Synthetic endoperoxides with a desymmetrized structure have demonstrated promising physiochemical and in vivo properties.

Recent studies show that, if not urgently addressed, antimicrobial resistance (AMR) could result in 39 million deaths between 2025 and 2050. The burden of AMR is highest in low-and-middle-income-countries, with the incidence and prevalence of resistance being particularly widespread throughout Africa. LifeArc has announced a significant £5 million investment to co-establish a new Centre for Translational AMR Research (CTAR) Programme at the Drug Discovery and Development Centre (H3D), University of Cape Town. This groundbreaking collaboration aims to address the urgent global health threat posed by AMR by developing first-in-class therapeutics for infections caused by multidrug-resistant (MDR) Gram-negative bacteria. #drugdiscovery #drugdevelopment #amr #antimicrobialresistance #scienceforafrica

We are working AI based drugs may go a long way

#Simulationrun. Will you put yourself in the patient’s shoes? How do you practice safety? This picture is just about this. Trusting the team to take blood from each other, running the tests, putting ourselves in the patients shoes. #stayingsafe #clinicaltrialday #capacitybuilding

Interesting Read! A malaria drug shows early potential as a treatment for PCOS in both rodents and humans. Exciting advancements like this showcase the importance of innovative research in medical science. Check out the full article here: https://lnkd.in/e9sNNS7K #Biotech #MedicalResearch #PCOS #CBB #UniversityOfIowa

Artemisia Afra & Tuberculosis Post Series: Breaking Research In order to spread awareness about recent advances in medicinal plants & natural products science, this post series is intended to highlight some of the recently published research in the literature.  Today’s highlight:   An O-methylflavone from Artemisia afra kills non-replicating hypoxic Mycobacterium tuberculosis.  Kellogg JJ, Alonso MN, Jordan RT, Xiao J, Cafiero JH, Bush T, Chen X, Towler M, Weathers P, Shell SS. J Ethnopharmacol. 2024 Oct 28;333:118500. Epub 2024 Jun 27. PMID: 38944359   This research investigates a compound, an O-methylflavone isolated from Artemisia afra, and its efficacy against Mycobacterium tuberculosis under low-oxygen, non-replicating conditions—similar to latent TB infections. O-methylflavone demonstrated the ability to kill hypoxic TB cells effectively, suggesting its potential as a promising alternative or adjunct in TB treatment, particularly for drug-resistant or latent forms. The findings support further exploration of Artemisia afra derivatives as viable options in addressing tuberculosis.   Full Text Link: https://lnkd.in/grw69YMS   #medicinalplants #naturalproducts #research